HC Wainwright Reiterates Buy Rating for ASLAN Pharmaceuticals (NASDAQ:ASLN)

HC Wainwright reiterated their buy rating on shares of ASLAN Pharmaceuticals (NASDAQ:ASLN) in a report released on Friday, Benzinga reports. The brokerage currently has a $9.00 price target on the stock.

Separately, Piper Sandler reaffirmed an overweight rating and issued a $10.00 price target (down previously from $15.00) on shares of ASLAN Pharmaceuticals in a research note on Wednesday, March 13th.

ASLAN Pharmaceuticals Price Performance

NASDAQ ASLN opened at $0.42 on Friday. The company’s fifty day moving average is $0.60 and its two-hundred day moving average is $0.67. The firm has a market capitalization of $6.94 million, a price-to-earnings ratio of -0.15 and a beta of 1.52. ASLAN Pharmaceuticals has a 52-week low of $0.39 and a 52-week high of $4.69.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last announced its quarterly earnings data on Friday, April 12th. The company reported ($0.78) earnings per share for the quarter. As a group, sell-side analysts expect that ASLAN Pharmaceuticals will post -2.68 earnings per share for the current fiscal year.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.